ClinicalTrials.gg
RecruitingNCT05215704EX VIVOUpdated Feb 14, 2024

Ex Vivo Characterization and Targeting of the Latent HIV Infected Reservoir to Cure HIV

An observational study in HIV Infections, HIV-1-infection and HIV-2 Infection, sponsored by Erasmus Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-14.

Sponsored by Erasmus Medical Center · Observational

How we know

From the registry’s dates

  • Started Jan 2012; still recruiting 14 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 86 studies in HIV Infections with a site in Netherlands — 6 open to participants now, 10 under way, 2 of them phase 3. HIV Infections · Netherlands.

Planned enrollment
8th of 10
40 · median 330
Started
2012
with 1 other
Observational
10 of 86
3 open now
Registered
79th of 86
by date
Lead sponsor
5 of 86
Erasmus Medical Center

Among the 86 studies in HIV Infections with a site in Netherlands, this one is the 8th largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2012, is one of 10 observational ones, and was the 79th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

6 of the 86 studies in HIV Infections with a site in Netherlands are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in HIV Infections with a site in Netherlands, or all of them as a file.
02

Study summary

Combination antiretroviral therapy (cART) blocks intracellular human immunodeficiency virus (HIV) replication in CD4+ T-lymphocytes, but fails to eliminate latent HIV infected CD4+ T-lymphocytes. About 7 (range \<1-100) in 106 of these cells are latently infected and can cause reactivation of proviral HIV when cART is stopped. These latently infected cells form the reservoir and must be targeted in order to cure HIV. We would like to further investigate this reservoir and assess potential interventions to eradicate it. One promising option is to further study the influence of HIV latency disruptors (latency reversing agents, LRA) on the HIV infected reservoir. These agents are used in shock and kill strategies that disrupt latency by LRA followed by the selective (induced) killing of the reservoir cell due to viro-pathogenic effects.

For accurate assessment of the reservoir and potential cure strategies, including the impact of LRA on the reservoir, a large reservoir and sufficient cells for analysis are desirable. Our understanding on the reservoir comes from in vitro lymphocyte models and early ex vivo studies. Additional studies of patients with different clinical phenotypes including untreated versus treated versus the rare individuals that control HIV spontaneously are increasingly relevant to the field. Especially this last category represent biological examples of viral control without cART and are useful to study the factors that set them apart from those that need treatment for their HIV. This study aims to deepen our understanding of the HIV reservoir and cure strategies, foremost, shock and kill strategies. We will do this by setting up a durable ex vivo platform for HIV reservoir and cure studies of which the samples can be used for hypothesis generation for in-vivo studies.

A project from the Erasmus MC HIV Eradication Group (EHEG).

Read the detailed description

This is a prospective cross-sectional cohort study used for ex vivo studies using material from HIV infected individuals. Peripheral blood mononuclear cells (PBMC's) and whole blood are obtained through leukapheresis and blood sampling at a single timepoint. Relevant clinical data will be collected to support interpretation of ex vivo experimental results. In vitro experiments are performed on patient derived material. In a substudy, patients can consent to longitudinal follow up with yearly sampling for 4 years.

Reservoir characteristics and efficacy of shock and kill strategies as defined in the endpoints will be explored between patients with different HIV clinical phenotypes. This allows us to identify discriminative factors useful to develop future cure strategies in clinic. We will therefore aim to include the following patients groups in the cohort:

  • HIV-1 patients including B and non-B subtypes patients
  • HIV-2 patients
  • Long term non progressors (plasma HIV-RNA \<2000c/mL without cART)
  • Elite controllers (plasma HIV-RNA \<50c/mL without cART)
  • Post-treatment controller (plasma HIV-RNA \<2000c/mL after permanent cART interruption)
03

Conditions studied

  • HIV Infections
  • HIV-1-infection
  • HIV-2 Infection

Browse trials for

Keywords

  • HIV
  • HIV cure
  • HIV reservoir
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Otherwise healthy adult HIV infected patients will be recruited at the Erasmus MC outpatient clinic of infectious diseases

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or older.
  2. Confirmed -1 or HIV-2 infection.

Exclusion criteria

Exclusion Criteria:

  1. Inability to place 2.5 cm venous catheter or perform phlebotomy
  2. Major comorbidities:

    A. Severe symptomatic anemia B. Recent symptomatic cardiovascular event (unstable angina pectoris, decompensated heart failure, myocardial infarction).

  3. The inability to participate due to any other relevant medical, social, environmental, psychological, factors or according to the treating physician's judgement
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. The number of HIV patients with a measurable proviral reservoir measured by molecular, flowcytometric and culture based assays

    Time frame: 10-15 years

Secondary outcomes

  1. The level of reactivation of latently HIV infected PBMCs after treatment ex vivo with established and novel HIV cure compounds (alone and in combination) as assessed by cell-associated HIVRNA.

    Time frame: 10-15 years

  2. The HIV reservoir size and activity as assessed by molecular, flowcytometric, and culture based assays ex vivo.

    Time frame: 10-15 years

  3. The HIV reservoir susceptibility to shock and kill strategies as assessed by molecular, flowcytometric, and culture based assays.

    Time frame: 10-15 years

  4. The HIV reservoir size, activity, and susceptibility to shock and kill strategies in relation to clinical phenotypes.

    Time frame: 10-15 years

  5. To measure predictive biomarkers of the size and activity of the latent HIV reservoir as assessed by molecular, flowcytometric and culture based assay ex vivo.

    Time frame: 10-15 years

  6. The number of newly setup assays that measure the size of the proviral reservoir and are validated with current established molecular, flowcytometric and culture based assays.

    Time frame: 10-15 years

07

Study locations

1 of 1 sites recruiting
  • Erasmus Medical Centre
    Rotterdam, Netherlands
    Recruiting
    • Rokx Casper, MD PhD · Contact
    • Casper Rokx, MD PhD · Principal investigator
    • Tokameh Mahmoudi, PhD · Principal investigator
    • Rob Gruters, PhD · Principal investigator
    • Peter Katsikis, Prof · Principal investigator
    • Shringar Rao, PhD · Sub investigator
    • Raquel Crespo Galvan, MSc · Sub investigator
    • Shahla Romal · Sub investigator
    • Tonmoy Hossain, MSc · Sub investigator
    • Henrieke Prins, MD · Sub investigator
    • Albert Groenendijk, MD · Sub investigator
    • Kathryn Hensley, MD · Sub investigator
    • Cynthia Lungu, MSc · Sub investigator
    • Peter te Boekhorst, MD PhD · Sub investigator
    • Yvonne Muller, PhD · Sub investigator
    • Els van Nood, MD PhD · Sub investigator
    • Mariana Mendonca melo, MD · Sub investigator
    • Annelies Verbon, Prof · Sub investigator
    • Jeroen van Kampen, MD PhD · Sub investigator
    • David vd Vijver, PharmD PhD · Sub investigator
    • Birgit Koch, Prof · Sub investigator
    • Thibault Mespede, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2012 (actual). Primary completion is estimated for Dec 2030, 227 months after the start.

Of 187 non-industry observational studies under HIV Infections, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 227 months is above that.

Counting every sponsor, half of 201 studies reached it within 38 months; a quarter within 16 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2021
First posted
Jan 31, 2022
StartActual
Jan 1, 2012
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2030
Last update
Feb 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05215704
Responsible party
Casper Rokx (Principal Investigator, Erasmus Medical Center) — Principal investigator
First posted
Jan 31, 2022
Start date
Jan 1, 2012
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Feb 14, 2024

Study contacts

Casper Rokx, MD PhD
Contact
c.rokx@erasmusmc.nl
Rob Gruters, PhD
Contact
r.gruters@erasmusmc.nl
Casper Rokx, MD PhD
principal investigator · Erasmus Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion